Corresponding author: Konstantin Tachkov ( tachkov@outlook.com ) Academic editor: Maya Georgieva
© 2019 Konstantin Tachkov, Konstantin Mitov, Alexandra Savova.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Tachkov K, Mitov K, Savova A (2019) Predicting the outcomes and costs for a cohort of 426 patients with Chronic Obstructive Pulmonary Disease (COPD) in Bulgaria through a Markov model. Pharmacia 66(2): 53-57. https://doi.org/10.3897/pharmacia.66.e35162
|
The aim was to estimate the economic burden, as well as rate of progression of COPD for a cohort of 426 patients for a 10-year period. A total of 426 patients from 19 regions with Chronic Obstructive Pulmonary Disease were enrolled in a representative, ambispective, national study for Bulgaria. Patients were recorded on disease stage, occupation, smoking habits and medication. Cost of treatment was calculated and a 10-year one-way Markov model was used by employing transition probabilities and quality of life data from available literature. Costs and outcomes were recorded and a cost-effectiveness acceptability curve (CEAC) was established.
Out of all patients included in the study 288 were non-smokers with a mortality percentage after 10 years of 42.7%. Smokers showed faster transition rate with 139 of them transitioning to more severe states and mortality was 54.6%. The incremental cost-effectiveness ratio (ICER) was 863.75 BGN. Patients who smoked had a lower quality of life – cumulatively for the 10-year period QALY = 623.51 for smokers vs. 1557.51 for non-smokers, but also lower costs for treatment (538 007.52 BGN vs. 1 344 757.95 BGN) accounted by the high transition rate and mortality amongst that group. Relatively few non-smokers transitioned from a less severe to a more severe state (6%), while most of the very severe stage patients experienced a lethal outcome within 10 years (81%).
Despite the higher costs associated with the disease, the Quality of Life and lower transition probability would enable patients to live a normal life. The ICER was well below the WHO threshold.
COPD, Markov Model, Pharmacotherapy, Cost-effectiveness
Chronic Obstructive Pulmonary Disease (COPD) is rapidly becoming a hugely significant disease, with estimates pointing towards it becoming the second most common diagnosis by 2030 (
The challenge in tackling the disease is two-fold. On the one hand, the ageing population of European Countries, in combination with new medicines and medical devices which prolong life, has increased the frequency of people developing chronic diseases (
Bulgaria suffers in all 3 aforementioned aspects. A total of 39% of the adult population over 40 year of age are smokers (
The field of COPD in Bulgaria also has not been studied recently in depth (
The aim was to estimate the economic burden, as well as the rate of progression of COPD for a cohort of 426 patients for a 10-year period.
In 2015, 426 patients were recruited from Bulgaria with a diagnosis of COPD, with every 5th patient, who entered a doctor’s practice, asked to participate. After signing consent forms, patients were followed throughout the year and information on pharmacotherapy, smoking status, age, sex, FEV1/FEC, occupation and disease stage was collected.
The Global Initiative for COPD (GOLD) has classified the disease into 4 stages corresponding to GOLD A, GOLD B, GOLD C and GOLD D. The cost of treatment for each GOLD group (A, B, C and D) (
The constructed model, previously expanded in another publication (Tachkov 2018), was one-way, with no new incidence programmed into it and it consisted of the 4 GOLD groups (A, B, C and D) and death as an absorbing state. Three-month transition probabilities were taken from
Smokers and non-smokers initial distribution and cost and utility data.
GOLD A | GOLD B | GOLD C | GOLD D | Source | |
Smokers (%) | 7 | 49 | 23 | 60 | Tachkov 2018 |
Non-smokers (%) | 23 | 96 | 40 | 129 | Tachkov 2018 |
Mean therapy cost (SD) | 438 (349.43-523.56) | 591 (505.43 -676.52) | 773 (687.44-858.56) | 790 (704.44-875.56) |
|
Quality Adjusted Life Years (QALY) | 0.85 | 0.81 | 0.76 | 0.66 |
|
In this study we explored what would happen to the enrolled patients. The model was set to run for 10 years and the Incremental Cost-Effectiveness Ratio was calculated for 2 groups of patients – smokers and non-smokers. Ex-smokers were put in the non-smoker category if they had quit more than a year ago.
The mortality percentage was calculated for both sub-groups in the cohort, the value of each Life Year Saved (LYS) was obtained and an ICER was calculated.
A deterministic (tornado diagram) and probabilistic sensitivity analysis (Monte Carlo simulation) were carried out and a cost-effectiveness acceptability curve (CEAC) was constructed. The margin of change for values was ±30% for the deterministic analysis and the Monte Carlo simulation consisted of 1000 recalculations of the ICER. The CEAC showed the price range at minimum and maximum, where ICER was 0% or 100% within the scope.
The majority of our patients were non-, or ex-smokers, but already in late stages of the disease. Nonetheless, they had the most control over the disease with very few patients transitioning to a more severe state – 19 patients (6%). Mortality was high in the GOLD D subgroup (81.3% of patients). This accounts for the high cost and utility values accumulated by non-smokers in the model (Table
Model value results for non-smokers.
Disease Stage | GOLD A | GOLD B | GOLD C | GOLD D | DEAD |
Initial Distr. | 23 | 96 | 40 | 129 | 0 |
Cycle 10 | 21 | 87 | 32 | 24 | 124 |
SUM COSTS = 1 344 758 | SUM QALY = 1557.51 | CER = 863.4 |
Smokers, on the other hand, showed faster turn-over and high mortality. A total of 91.6% of patients in GOLD D had experienced a lethal outcome and 21 patients (31.5%) from GOLD A and B had progressed (Table
Model value results for smokers.
Disease Stage | GOLD A | GOLD B | GOLD C | GOLD D | DEAD |
Initial Distr. | 7 | 49 | 23 | 60 | 0 |
Cycle 10 | 4 | 31 | 22 | 5 | 77 |
SUM COSTS = 538 007.52 | SUM QALY = 623.51 | CER = 862.87 |
The incremental ratio between the two CER values was 863.75BGN with the incremental value for each LYS being 8067.5 BGN. (Table
Summarised ICER values for QALY and LYS.
Group | SUM COSTS | SUM QALYs | CER | ICER QALY |
Non-smokers | 1344757.95 | 1557.51 | 863.402 | |
Smokers | 538007.52 | 623.51 | 862.869 | 863.76 |
GROUP SUM COSTS | SUM LYS | ICER LYS | ||
Non-smokers | 1344757.95 | 165 | 8150.048 | |
Smokers | 538007.52 | 65 | 8277.038 | 8067.50 |
Despite these differences, the Monte-Carlo cluster revealed a homogenous dispersion of data points (Figure
In terms of the deterministic sensitivity analysis, the lowest ICER for QALY was observed when the costs for non-smokers were 30% lower (531.5 BGN) and the highest when their costs were 30% higher (1295.69 BGN). For LYS, the minimal ICER was 4964.22 BGN when the cost of therapy for non-smokers was 30% lower, while maximal value was 13 028.27 BGN when LYS for non-smokers was 30% lower (Figures
To our knowledge, this is the first Bulgarian COPD Markov model. It tries to simulate the progression of disease in a cohort of 426 patients, based on their smoking status. It also provides information regarding which stage of disease is the most difficult to control, since large-scale observational studies are not always economically feasible, in order to obtain such information.
Patients in the studied cohort are a representative sample of the country and reveal that diagnosis in GOLD A is a rare phenomenon. Overall, only 7% of all patients in the cohort were in GOLD A. The other important aspect to be considered is that smoking status is an acute problem for the country where established data from the National Statistics Institute (NSI) show that 39% of the population over 40 smoke, and if people from all age groups are included in the statistics, the estimates show that more than 50% of the entire country are current smokers (National Statistical Institute). We have used this data, along with our model elsewhere, to predict what would be the disease prevalence and progression for the wider Bulgarian population, coupled with the costs and outcomes (Tachkov 2018). The results from our current model were interesting and present a hypothetical view of how the next 10 years would unfold for the patient, for whom we had only one year of observation. Despite the short follow-up period, our results are consistent with documented literature on how smoking affects the natural progression of COPD (
Thus, it is possible to conclude that the disease will have an increasing impact on Bulgarian society in the coming years. Therefore, it was necessary to evaluate the cost-effectiveness and rate of progression for both non-smokers and smokers, in order to help decision-makers and patients make more informed decisions. The main strength of the model is that it is based on real-world data, taken from real-life pulmonologist practices.
It combines this with previous studies in the field on lung function decline and benefits of adequate disease control (
A limitation of the model is the fact that it is a one-way, static model and cannot draw definite conclusions on whether or not smoking cessation is achieved in all people afflicted by the disease. Due to the model’s nature, costs remained stable, thus only one aspect of the disease was reflected, not accounting for the possibility of back-transitions. The high variation of 30% in the sensitivity analysis was used to compensate for this shortcoming and it is worth pointing out, that in all cases, the ICER was well below the established threshold of 3 times GDP per capita. This would indicate that the cost-effectiveness of treatments can allow for an addition of a prevention programme.
The other limitation is the short term, real-life observation of the patients for a 2 year time period.
This work is a logical and scientific development of the already published study (Tachkov 2018). The first study is testing the hypothesis of cost-effectiveness of the COPD therapy for the general population and this study is predicting the pharmacotherapy results for a particular patient cohort. Both studies confirm that the constructed model could be used for a real life prediction of the cost-effectiveness of COPD pharmacotherapy. In addition, both validated the results that the treatment of smokers and non-smokers is cost – effective for the Bulgarian population.
Despite the higher costs associated with the disease, the Quality of Life and lower transition probability would enable non-smokers to live longer lives with better disease control. The ICER was well below the WHO threshold making the cost per additional benefits cost-effective. For patients who want to achieve adequate disease control, smoking cessation is necessary, since smokers have higher mortality rates. A broader burden of disease study from a societal perspective is necessary to estimate the savings that would be achieved from a smoking-cessation programme.